Top Markets
Coin of the day
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
Rang in Aktien #39175
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
Aktienkurs
$0.378
Zuletzt synchronisiert: 2024-05-24
Marktkapitalisierung
$618.41K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel NeuBase Therapeutics, Inc. (NBSE)

Kategorie

Kursverlauf für NeuBase Therapeutics, Inc. (NBSE)
Höchster Schlusskurs: $0.39 am 2024-05-01

Niedrigster Schlusskurs: $733.33 am 2004-05-01
Kursverlauf der Aktie von NeuBase Therapeutics, Inc. von 2004 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2024 -49.90%
2023 -81.22%
2022 -92.72%
2021 -64.02%
2020 7.86%
2019 205.09%
2018 -92.38%
2017 -19.09%
2016 -60.75%
2015 75.31%
2014 6.31%
2013 49.44%
2012 167.16%
2011 169.72%
2010 -59.63%
2009 129.24%
2008 14.29%
2007 -48.15%
2006 -74.29%
2005 -15.32%
2004 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$517.18 32.51%
US
$857.76 31.47%
NL
$728.05 6.60%
CH
$1.07K -6.40%
KR
$254.79 12.56%
BE